Angiotensin Receptor Blockers (ARBs) Market Report 2025

The angiotensin receptor blockers (ARBs) market size has grown steadily in recent years. It will grow from $8.51 billion in 2024 to $8.87 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to hypertension epidemic, clinical efficacy, cardiovascular disease burden, renal protection, clinical guidelines, ARBs as first-line treatment, cost-effectiveness.

The angiotensin receptor blockers (ARBs) market size is expected to see steady growth in the next few years. It will grow to $10.76 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to precision medicine approaches, focus on combination therapies, global expansion of market, biomarker-based treatment strategies, government initiatives, increased awareness of hypertension. Major trends in the forecast period include telemedicine adoption, research and development investments, generic competition and patent expirations, digital health solutions for medication adherence, biosimilar competition.

The rising incidence of chronic kidney diseases is anticipated to drive the growth of the angiotensin receptor blockers (ARBs) market in the coming years. Chronic kidney disease (CKD) is a long-term condition marked by the gradual decline of kidney function over time. Angiotensin receptor blockers are utilized in managing CKD by lowering blood pressure, providing renal protection, addressing diabetic nephropathy, and managing cardiovascular complications. For instance, in June 2023, a report from the University of Oxford, a UK-based higher education institution, indicated that the prevalence of CKD is expected to increase by 4% from 8.27 million to 8.61 million people in the UK between 2022 and 2032. Therefore, the rising prevalence of chronic kidney diseases is fueling the growth of the angiotensin receptor blockers market.

The growing prevalence of hypertension is also expected to drive the growth of the angiotensin receptor blockers (ARBs) market in the future. Hypertension, commonly referred to as high or elevated blood pressure, is characterized by persistently high pressure in the blood vessels. ARBs are a category of medication frequently prescribed for hypertension, working by relaxing and widening blood vessels to facilitate smoother blood flow. As the incidence of hypertension increases among the population, so will the demand for angiotensin receptor blockers. For instance, in March 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 1.28 billion adults aged 30 to 79 worldwide have hypertension, with two-thirds residing in low- and middle-income countries. It is estimated that 46% of adults with hypertension are unaware of their condition. Additionally, in December 2023, the Australian Bureau of Statistics, an Australia-based government agency, reported that more than one in ten individuals (11.6% or 3 million) in 2022 indicated having hypertension. Consequently, the rising prevalence of hypertension is driving the growth of the angiotensin receptor blockers (ARBs) market.

The escalating prevalence of hypertension diseases is poised to drive the expansion of the angiotensin receptor blockers (ARBs) market in the foreseeable future. Hypertension, characterized by persistently elevated blood pressure, finds treatment through medications such as angiotensin receptor blockers (ARBs), which operate by widening blood arteries, facilitating smoother blood flow. This increased prevalence of hypertension among the populace is expected to heighten the demand for angiotensin receptor blockers. For instance, data from the Centers for Disease Control and Prevention (CDC) in July 2023 highlighted hypertension as a leading cause of mortality in the US, accounting for 691,095 fatalities in 2021. Approximately 47% of US adults, totaling 116 million individuals, suffer from hypertension, with only 24% having it under control. An estimated 34 million individuals recommended medication may necessitate prescription initiation, emphasizing the substantial demand for treatment. This data underscores how the rising prevalence of hypertension diseases is fueling the growth of the angiotensin receptor blockers (ARBs) market.

Major companies in the angiotensin receptor blocker market are focused on developing advanced products, such as angiotensin receptor neprilysin inhibitors, to improve treatment options and enhance outcomes for patients with cardiovascular conditions. Angiotensin receptor neprilysin inhibitors (ARNIs) are a category of medications used for heart failure treatment. For example, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, launched sacubitril + valsartan tablets specifically designed for heart failure, particularly targeting heart failure with reduced ejection fraction (HFrEF). This combination falls under the ARNI class of medications. Sacubitril enhances the natriuretic peptide (NP) system, helping to relieve fluid overload and promote vasodilation, while valsartan inhibits the renin-angiotensin system (RAS) to reduce blood pressure and lessen the heart's workload. Together, these medications effectively alleviate heart failure symptoms, lower the risk of cardiovascular mortality, and decrease the likelihood of hospitalization due to heart failure. They are marketed under the brand name Sacu V.

Major companies operating in the angiotensin receptor blockers (ARBs) market are advancing the development of prescription medications to enhance the treatment of conditions such as hypertension and heart failure while improving patient outcomes. Prescription medications are drugs that can only be legally dispensed to patients when prescribed by a licensed healthcare professional, including doctors, nurse practitioners, or dentists. For instance, in July 2022, Lupin, an India-based transnational pharmaceutical company, received approval from the Food and Drug Administration (FDA), a US federal agency responsible for public health protection, for Azilsartan Medoxomil Tablets. Azilsartan Medoxomil Tablets are a prescription medication primarily used for treating hypertension (high blood pressure). They serve as an effective treatment option for hypertension, aiding in blood pressure reduction and decreasing the risk of cardiovascular events. This medication belongs to the angiotensin II receptor blocker (ARB) class, working by relaxing blood vessels to facilitate easier blood flow, thus helping to lower blood pressure. Reducing blood pressure contributes to the prevention of strokes, heart attacks, and kidney issues.

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma.

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the angiotensin receptor blockers (arbs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Angiotensin receptor blockers (ARBs) are medications designed to widen blood vessels, addressing conditions such as high blood pressure (hypertension), heart failure, and kidney disease, particularly in individuals with diabetes. These drugs work by blocking the effects of angiotensin, a chemical in the body that causes blood vessels to constrict, leading to increased blood pressure and added strain on the heart.

The primary products within the class of angiotensin receptor blockers (ARBs) include valsartan, losartan, irbesartan, azilsartan, and olmesartan. Losartan, for instance, is an ARB that not only treats hypertension but also reduces the risk of stroke and manages diabetic nephropathy. These medications find applications in various medical conditions, such as hypertension, cardiovascular diseases, kidney diseases, among others, and are utilized by end-users such as hospitals, specialty clinics, and ambulatory surgical centers.

The angiotensin receptor blockers (ARBs) market research report is one of a series of new reports that provides angiotensin receptor blockers (ARBs) market statistics, including angiotensin receptor blockers (ARBs) industry global market size, regional shares, competitors with a angiotensin receptor blockers (ARBs) market share, detailed angiotensin receptor blockers (ARBs) market segments, market trends and opportunities, and any further data you may need to thrive in the angiotensin receptor blockers (ARBs) industry. This angiotensin receptor blockers (ARBs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The angiotensin receptor blockers (ARBs) market consists of sales of candesartan and eprosartan. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.